Impact of glucagon‐like peptide‐1 receptor agonism‐based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta‐analysis
Authors' conclusion
GLP1RA-BTs are beneficial in PAD, especially in reducing the need for revascularization.
Study context
- Population
- Patients with peripheral artery disease (PAD) and/or T2D; PAD cohort (studies exclusively enrolling PAD) and T2D cohort (broader T2D populations, PAD <15%)10 studies PAD cohort
- Comparison
- GLP-1 RA-based therapies vs controls
- Outcome
- Major adverse limb events (MALEs)
Methodological detailsupdated, separate analyses for PAD cohort and T2D cohort
- Updated
- Separate analyses for PAD cohort and T2D cohort
Pooled result
As reported in the abstract
MALE
GLP1RA-BTs vs ControlsOdds ratio (CI)P value
PAD cohort; I2 = 94%
0.66(0.44–1.00)
P = 0.05T2D cohort; I2 = 0%
0.70(0.57–0.85)
P = 0.0005Further pooled results
| Outcome | OR (CI) | P value | |
|---|---|---|---|
| All-cause mortalityGLP1RA-BTsvs ControlsPAD cohort; I2 = 97% | 0.55 (0.38–0.78) | P = 0.0008 | |
| All-cause mortalityGLP1RA-BTsvs ControlsT2D cohort; I2 = 85% | 0.55 (0.43–0.69) | P < 0.001 | |
| MACE (PAD cohort)I2 = 85% | 0.68 (0.52–0.88) | P = 0.004 | |
| MI (PAD cohort)I2 = 42% | 0.68 (0.51–0.91) | P = 0.009 | |
| Revascularization (PAD cohort)I2 = 0% | 0.85 (0.80–0.90) | P < 0.001 | |
| Amputations (T2D cohort)I2 = 0% | 0.58 (0.48–0.69) | P < 0.001 | |
| 0.20.5125Odds ratio (log scale) |
Original publication
Impact of glucagon‐like peptide‐1 receptor agonism‐based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta‐analysis. Diabetes Obes Metab. Published 22 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →